Get the Stockscreener App
3.64
5.21%
-0.20
Absci Corp stock is traded at $3.64, with a volume of 4.86M.
It is down -5.21% in the last 24 hours and up +7.06% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
See More
Previous Close:
$3.84
Open:
$3.83
24h Volume:
4.86M
Relative Volume:
0.89
Market Cap:
$547.35M
Revenue:
$4.21M
Net Income/Loss:
$-97.67M
P/E Ratio:
-3.914
EPS:
-0.93
Net Cash Flow:
$-70.76M
1W Performance:
+1.68%
1M Performance:
+7.06%
6M Performance:
+28.17%
1Y Performance:
-1.09%
1-Day Range:
$3.50
$3.83
1-Week Range:
$3.36
$4.06
52-Week Range:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.64 | 577.43M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Absci (NASDAQ:ABSI) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Absci’s ABS-201 stimulates human hair follicle growth ex vivo - BioWorld MedTech
Absci’s ABS-201 antibody shows promise for hair regrowth treatment - Investing.com
Absci’s ABS-201 antibody shows promise for hair regrowth treatment By Investing.com - Investing.com Canada
Absci Reports New Human Ex Vivo Data Demonstrating That - GlobeNewswire
Is Absci Poised for a Surge? - StocksToTrade
Absci, former U.S. soccer player Donovan announce partnership - TipRanks
Absci Corporation Partners with Landon Donovan to Address Androgenetic Alopecia and Advance Therapeutic Innovations - Quiver Quantitative
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewswire
Absci (NASDAQ:ABSI) Transforms Biotechnology With AI Integration - Kalkine Media
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine? - simplywall.st
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - The Globe and Mail
Absci (NASDAQ:ABSI) Stock Price Up 10.8%Still a Buy? - MarketBeat
Absci doses first volunteers in phase 1/2a trial of hair loss antibody - Investing.com Nigeria
Absci doses first volunteers in phase 1/2a trial of hair loss antibody By Investing.com - Investing.com South Africa
Absci Stock’s Financial Prospects: An In-Depth Analysis - StocksToTrade
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial - simplywall.st
Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com
Absci announces first participants dosed in Phase 1/2a HEADLINE trial - TipRanks
Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance
Absci Announces First Participants Dosed In Phase 1/2A Headline Trial - TradingView
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - The Manila Times
Will Absci Corporation stock deliver shareholder valueJuly 2025 Opening Moves & AI Optimized Trade Strategies - Newser
Absci stock price target raised to $9 from $8 at Jones Trading By Investing.com - Investing.com South Africa
Absci stock price target raised to $9 from $8 at Jones Trading - Investing.com Canada
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $9 - 富途牛牛
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci Corp. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Will Absci Corporation see short term momentumWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
How Absci Corporation stock benefits from tech adoptionJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - newser.com
Can trapped investors hope for a rebound in Absci CorporationGlobal Markets & Community Shared Stock Ideas - newser.com
Can Absci Corporation stock double in next 5 yearsMarket Growth Report & Expert Approved Momentum Trade Ideas - newser.com
Will Absci Corporation stock maintain growth storyJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Absci Corp’s Earnings Call Highlights Strategic Growth - MSN
Can Absci Corporation stock deliver sustainable ROE2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Absci (ABSI) Valuation in Focus as Clinical Expansion and Partnership Efforts Gather Pace - Yahoo Finance
Can Absci Corporation stock surprise with earnings upsideJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Real time pattern detection on Absci Corporation stockPortfolio Update Summary & Proven Capital Preservation Methods - newser.com
Absci Corporation Advances AI-Driven Therapeutics - MSN
Absci’s Cash Reserves Bolster Future Financial Confidence - timothysykes.com
Absci Corporation (NASDAQ:ABSI) Q3 2025 Earnings Call Transcript - Insider Monkey
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Absci Corp Stock (ABSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):